Ohio State University (OSU) and Biosortia Pharmaceuticals Partner to Identify Anti-Cancer Drugs


Date: 01 April 2013


Description:

Ohio State University (OSU) and Biosortia Pharmaceuticals have partnered to discover and develop drugs targeting human colon cancer. Dr. Kinghorn of OSU will be responsible for the separation and identification of anti-cancer components from cyanobacteria extracts provided by Biosortia. The collaboration is a reinvigoration of the industry's need to find novel inspiration for old cancer targets.

Source: http://www.drugdiscoverynews.com

Announcement web link

Contact Name: Kelsey Kaustinen

Contact E-mail: kaustinen@drugdiscoverynews.com